Skip to main content

Biogen ZURZUVAE revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

ZURZUVAE revenue at Biogen came to $84.4M for the quarter to 30 Sep 2026, up 52.6% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$0Sep 2023$12.4MMar 2024$14.9MJun 2024$22.0MSep 2024$22.9MDec 2024$27.7MMar 2025$46.4MJun 2025$55.3MSep 2025$65.7MDec 2025$55.4MMar 2026$70.8MJun 2026$84.4MSep 2026
Biogen ZURZUVAE revenue, every reported period
Period endingZURZUVAE revenueChange on a yearFiled
30 Sep 2026$84.4Mup 52.6%28 Oct 2026
30 Jun 2026$70.8Mup 52.6%29 Jul 2026
31 Mar 2026$55.4Mup 100.0%29 Apr 2026
31 Dec 2025$65.7Mup 186.9%6 Feb 2026
30 Sep 2025$55.3Mup 151.4%30 Oct 2025
30 Jun 2025$46.4Mup 211.4%31 Jul 2025
31 Mar 2025$27.7Mup 123.4%1 May 2025
31 Dec 2024$22.9M—12 Feb 2025
30 Sep 2024$22.0M—30 Oct 2024
30 Jun 2024$14.9M—1 Aug 2024
31 Mar 2024$12.4M—24 Apr 2024
30 Sep 2023$0—8 Nov 2023
30 Jun 2023$0—25 Jul 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.